"A new method for early and accurate breast cancer screening has been developed by researchers at BenGurion University of the Negev and Soroka University Medical Center using commercially available technology.  The researchers were able to isolate relevant data to more accurately identify breast cancer biomarkers using two different electronic nose gas sensors for breath along with gaschromatography mass spectrometry GCMS to quantify substances found in urine.  In their study published in Computers in Biology and Medicine researchers detected breast cancer with more than  percent average accuracy using an inexpensive commercial electronic nose enose that identifies unique breath patterns in women with breast cancer. In addition their revamped statistical analyses of urine samples submitted both by healthy patients and those diagnosed with breast cancer yielded  percent average accuracy.  Breast cancer survival is strongly tied to the sensitivity of tumor detection accurate methods for detecting smaller earlier tumors remains a priority says Prof. Yehuda Zeiri a member of BenGurion Universitys Department of Biomedical Engineering. Our new approach utilizing urine and exhaled breath samples analyzed with inexpensive commercially available processes is noninvasive accessible and may be easily implemented in a variety of settings.  The study reports breast cancer is the most commonly diagnosed malignancy among females and the leading cause of death around the world. In  breast cancer accounted for  percent of all new cancers identified in the United States and was responsible for  percent of all cancerrelated deaths.  Mammography screenings which are proven to significantly reduce breast cancer mortality are not always able to detect small tumors in dense breast tissue. In fact typical mammography sensitivity which is  to  percent accurate decreases to  to  percent in dense tissue.  Current diagnostic imaging detection for smaller tumors has significant drawbacks dualenergy digital mammography while effective increases radiation exposure and magnetic resonance imaging MRI is expensive. Biopsies and serum biomarker identification processes are invasive equipmentintensive and require significant expertise.  Weve now shown that inexpensive commercial electronic noses are sufficient for classifying cancer patients at early stages says Prof. Zeiri. With further study it may also be possible to analyze exhaled breath and urine samples to identify other cancer types as well.   Study contributors include BenGurion University biomedical engineering researchers Prof. Yehuda Zeiri Or HermanSaffar Zvi Boger and Raphael Gonen Dr. Shai Libson a surgeon in the Breast Health Center at Soroka and Dr. David Lieberman an associate professor in BenGurion Universitys Joyce and Irving Goldman Medical School Faculty of Health Sciences.  About American Associates BenGurion University of the Negev American Associates BenGurion University of the Negev AABGU plays a vital role in sustaining David BenGurions vision creating a worldclass institution of education and research in the Israeli desert nurturing the Negev community and sharing the Universitys expertise locally and around the globe. As BenGurion University of the Negev looks ahead to turning  in  AABGU imagines a future that goes beyond the walls of academia. It is a future where BenGurion U. invents a new world and inspires a vision for a stronger Israel and its next generation of leaders. Together with supporters AABGU will help the University foster excellence in teaching research and outreach to the communities of the Negev for the next  years and beyond. Visit vision.aabgu.org to learn more.  AABGU which is headquartered in Manhattan has nine regional offices throughout the United States. For more information visit http"